在腹腔透析患者群体中,β阻塞剂使用与心力衰竭死亡率之间的关联:一项队列研究
Meizhu Gao1, Han Chen2, Fang Cao1,3
1Department of Nephrology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China.
Clinical kidney journal
|March 6, 2024
概括
在腹腔透析患者中,β-阻断剂治疗显著降低了心力衰竭死亡率. 这一发现突显了β-阻断剂作为潜在的关键治疗心力衰竭在末期病患者在PD.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在末期脏病 (ESRD) 患者中,β阻塞剂的预后意义在患有心力衰竭的腹透析 (PD) 患者中是不充分研究的.
- 关于β-阻断剂治疗对PD患者心力衰竭结果的影响存在有限的研究.
研究的目的:
- 调查β-阻断剂治疗对ESRD患者进行PD和心力衰竭的预后意义.
- 在这个特定的患者队列中确定β-阻断剂使用与心力衰竭相关死亡率之间的关联.
主要方法:
- 对608名PD患者 (2007年9月 - 2019年3月) 的回顾性分析,随访至2020年12月.
- 利用考克斯回归和倾向得分匹配加权分析来评估β阻塞剂使用和心力衰竭死亡率的危险比率.
- 雇佣了竞争风险和子组分析,以进一步验证发现.
主要成果:
- 贝塔抑制剂被处方给了56.1%的PD患者,43.4%患有心力衰竭,15.5%的死亡与心力衰竭有关.
- β阻塞剂的使用与心力衰竭死亡的调整后危险比率降低了43% (HR=0.36-0.89,P=0.013).
- 在使用β-阻断剂的患者中,即使考虑到相应的风险 (P=0.007),也观察到心力衰竭死亡率的累积风险明显较低. 使用β-阻断剂并没有影响全因死亡率.
结论:
- β抑制剂治疗与腹腔透析患者中心力衰竭相关的死亡率降低有关.
- 建议进行进一步的随机临床试验,以证实贝塔抑制剂对PD患者的益处.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338
01:22Heart Failure Drugs: Diuretics
375
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
375
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:27Dialysis
309
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
309
01:17Antihypertensive Drugs: Action of β1 Blockers
447
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
447
01:11Renal Failure: Dose Adjustments
88
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
88